Impact Events
MoreDate | Lead Company | Event | Type | Approval Change | Approval Likelihood |
---|---|---|---|---|---|
4/14/25 | Bristol (BMY) | Camzyos for Cardiomyopathy - Hypertrophic | Subscribers Only | Subscribers Only | Subscribers Only |
4/1/25 | Cerevance | CVN424 for Parkinson's Disease (PD) | Subscribers Only | Subscribers Only | Subscribers Only |
4/1/25 | Compass Therapeutics (CMPX) | Tovecimig for Biliary Tract Cancer | Subscribers Only | Subscribers Only | Subscribers Only |
3/31/25 | Eli Lilly (LLY) | LY3561774 for Dyslipidemia / Hypercholesterolemia | Subscribers Only | Subscribers Only | Subscribers Only |
3/31/25 | AstraZeneca (AZN) | AZD0780 for Dyslipidemia / Hypercholesterolemia | Subscribers Only | Subscribers Only | Subscribers Only |
Upcoming Catalysts
MoreExpected Date Range | Lead Company | Drug | Expected Catalyst |
---|---|---|---|
04/01/2025 | Subscribers Only | Subscribers Only | Company - Divestment/Spinoff |
04/12/2025 | Subscribers Only | Subscribers Only | Trial Data - Updated Results |
04/13/2025 | Subscribers Only | Subscribers Only | Trial Data - Updated Results |
04/15/2025 | Subscribers Only | Subscribers Only | Progress Update - Product Launch (U.S.) |
04/15/2025 | Subscribers Only | Subscribers Only | Trial Data - Updated Results |